Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy

Mary Ann A Etiebet, James Shepherd, Rebecca G. Nowak, Man Charurat, Harry Chang, Samuel Ajayi, Olufunmilayo Elegba, Nicaise Ndembi, Alashle Abimiku, Jean K. Carr, Lindsay M. Eyzaguirre, William A. Blattner

Research output: Contribution to journalArticle

Abstract

BACKGROUND: In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns. METHODS: Stored plasma from 349 adult patients on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens was assayed for HIV-1 RNA viral load, and samples with more than 1000copies/ml were sequenced in the pol gene. Analysis for resistance mutations utilized the IAS-US 2011 Drug Resistance Mutation list. RESULTS: One hundred and seventy-five samples were genotyped; the majority of the subtypes were G (42.9%) and CRF02-AG (33.7%). Patients were on ART for a median of 27 months. 90% had the M184V/I mutation, 62% had at least one thymidine analog mutation, and 14% had the K65R mutation. 97% had an NNRTI resistance mutation and 47% had at least two etravirine-associated mutations. In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P

Original languageEnglish (US)
Pages (from-to)553-561
Number of pages9
JournalAIDS
Volume27
Issue number4
DOIs
StatePublished - Feb 20 2013
Externally publishedYes

Fingerprint

Tenofovir
Drug Resistance
HIV-1
Mutation
Reverse Transcriptase Inhibitors
Viral Load
Therapeutics
etravirine
pol Genes

Keywords

  • drug resistance
  • HIV-1
  • non-B subtype
  • resource-limited settings
  • second line
  • tenofovir disoproxil fumarate
  • thymidine analog mutations

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Etiebet, M. A. A., Shepherd, J., Nowak, R. G., Charurat, M., Chang, H., Ajayi, S., ... Blattner, W. A. (2013). Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS, 27(4), 553-561. https://doi.org/10.1097/QAD.0b013e32835b0f59

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. / Etiebet, Mary Ann A; Shepherd, James; Nowak, Rebecca G.; Charurat, Man; Chang, Harry; Ajayi, Samuel; Elegba, Olufunmilayo; Ndembi, Nicaise; Abimiku, Alashle; Carr, Jean K.; Eyzaguirre, Lindsay M.; Blattner, William A.

In: AIDS, Vol. 27, No. 4, 20.02.2013, p. 553-561.

Research output: Contribution to journalArticle

Etiebet, MAA, Shepherd, J, Nowak, RG, Charurat, M, Chang, H, Ajayi, S, Elegba, O, Ndembi, N, Abimiku, A, Carr, JK, Eyzaguirre, LM & Blattner, WA 2013, 'Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy', AIDS, vol. 27, no. 4, pp. 553-561. https://doi.org/10.1097/QAD.0b013e32835b0f59
Etiebet, Mary Ann A ; Shepherd, James ; Nowak, Rebecca G. ; Charurat, Man ; Chang, Harry ; Ajayi, Samuel ; Elegba, Olufunmilayo ; Ndembi, Nicaise ; Abimiku, Alashle ; Carr, Jean K. ; Eyzaguirre, Lindsay M. ; Blattner, William A. / Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. In: AIDS. 2013 ; Vol. 27, No. 4. pp. 553-561.
@article{584a5adb90c649cd8702fef5f6e9deae,
title = "Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy",
abstract = "BACKGROUND: In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns. METHODS: Stored plasma from 349 adult patients on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens was assayed for HIV-1 RNA viral load, and samples with more than 1000copies/ml were sequenced in the pol gene. Analysis for resistance mutations utilized the IAS-US 2011 Drug Resistance Mutation list. RESULTS: One hundred and seventy-five samples were genotyped; the majority of the subtypes were G (42.9{\%}) and CRF02-AG (33.7{\%}). Patients were on ART for a median of 27 months. 90{\%} had the M184V/I mutation, 62{\%} had at least one thymidine analog mutation, and 14{\%} had the K65R mutation. 97{\%} had an NNRTI resistance mutation and 47{\%} had at least two etravirine-associated mutations. In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P",
keywords = "drug resistance, HIV-1, non-B subtype, resource-limited settings, second line, tenofovir disoproxil fumarate, thymidine analog mutations",
author = "Etiebet, {Mary Ann A} and James Shepherd and Nowak, {Rebecca G.} and Man Charurat and Harry Chang and Samuel Ajayi and Olufunmilayo Elegba and Nicaise Ndembi and Alashle Abimiku and Carr, {Jean K.} and Eyzaguirre, {Lindsay M.} and Blattner, {William A.}",
year = "2013",
month = "2",
day = "20",
doi = "10.1097/QAD.0b013e32835b0f59",
language = "English (US)",
volume = "27",
pages = "553--561",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy

AU - Etiebet, Mary Ann A

AU - Shepherd, James

AU - Nowak, Rebecca G.

AU - Charurat, Man

AU - Chang, Harry

AU - Ajayi, Samuel

AU - Elegba, Olufunmilayo

AU - Ndembi, Nicaise

AU - Abimiku, Alashle

AU - Carr, Jean K.

AU - Eyzaguirre, Lindsay M.

AU - Blattner, William A.

PY - 2013/2/20

Y1 - 2013/2/20

N2 - BACKGROUND: In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns. METHODS: Stored plasma from 349 adult patients on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens was assayed for HIV-1 RNA viral load, and samples with more than 1000copies/ml were sequenced in the pol gene. Analysis for resistance mutations utilized the IAS-US 2011 Drug Resistance Mutation list. RESULTS: One hundred and seventy-five samples were genotyped; the majority of the subtypes were G (42.9%) and CRF02-AG (33.7%). Patients were on ART for a median of 27 months. 90% had the M184V/I mutation, 62% had at least one thymidine analog mutation, and 14% had the K65R mutation. 97% had an NNRTI resistance mutation and 47% had at least two etravirine-associated mutations. In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P

AB - BACKGROUND: In resource-limited settings, HIV-1 drug resistance testing to guide antiretroviral therapy (ART) selection is unavailable. We retrospectively conducted genotypic analysis on archived samples from Nigerian patients who received targeted viral load testing to confirm treatment failure and report their drug resistance mutation patterns. METHODS: Stored plasma from 349 adult patients on non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens was assayed for HIV-1 RNA viral load, and samples with more than 1000copies/ml were sequenced in the pol gene. Analysis for resistance mutations utilized the IAS-US 2011 Drug Resistance Mutation list. RESULTS: One hundred and seventy-five samples were genotyped; the majority of the subtypes were G (42.9%) and CRF02-AG (33.7%). Patients were on ART for a median of 27 months. 90% had the M184V/I mutation, 62% had at least one thymidine analog mutation, and 14% had the K65R mutation. 97% had an NNRTI resistance mutation and 47% had at least two etravirine-associated mutations. In multivariate analysis tenofovir-based regimens were less likely to have at least three nucleoside reverse transcriptase inhibitor (NRTI) mutations after adjusting for subtype, previous ART, CD4, and HIV viral load [P

KW - drug resistance

KW - HIV-1

KW - non-B subtype

KW - resource-limited settings

KW - second line

KW - tenofovir disoproxil fumarate

KW - thymidine analog mutations

UR - http://www.scopus.com/inward/record.url?scp=84873413113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873413113&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32835b0f59

DO - 10.1097/QAD.0b013e32835b0f59

M3 - Article

C2 - 23079810

AN - SCOPUS:84873413113

VL - 27

SP - 553

EP - 561

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

ER -